title: Feasibility of adequate resectable rectal cancer treatment in a third-level hospital.
abstract: OBJECTIVE
  The aim of this study was to determine the feasibility, concerning compliance to protocol and recommended clinical practice guidelines, as well as efficacy results of multidisciplinary treatment (surgery, radiotherapy and chemotherapy) of resectable rectal cancer in a third-level hospital devoid of radiotherapy and clinical oncology units.
  
  
  METHODS
  A retrospective, single-institution analysis was completed for 45 consecutive patients diagnosed with resectable rectal cancer who entered an officially proposed multidisciplinary treatment protocol from October 1998 to September 2003. Adequacy of patient inclusion, according to clinical stage, was reviewed. Neoadjuvant radiotherapy schedule, surgery procedures and adjuvant chemotherapy indication were assessed. All treatment time intervals were analysed. Finally, efficacy results are discussed and contextualised by comparison with results of clinical trials which support this treatment strategy.
  
  
  RESULTS
  According to an independent board review, 3 patients (6.7%) with stage I rectal cancer, 31 patients (68.9%) with stage II and 11 patients (24.4%) with stage III rectal cancer were included. Radiotherapy dosage, volume and schedule were as planned. Median time from diagnosis to start of radiotherapy was 26.36 days (24.26- 28.57; CI 95%). Median duration of radiotherapy was 6.00 days (5.56-6.44; CI 95%). Median time from start of radiotherapy to surgery was 15.67 days (14.47-16.87; CI 95%). Median time from completion of radiotherapy to surgery was 10.67 days (9.53-11.81; CI 95%). Most of the patients underwent low anterior resection [23 patients (51.2%)] and abdominoperineal resection [16 patients (35.6%)]. Correlation between clinical and pathologic staging was as expected. Twenty-nine patients (64.4%) of the 45 that were initially included started adjuvant chemotherapy. A statistically significant relationship between pathologic stage (grouped I-II vs. III) and the use of adjuvant chemotherapy was found (p=0.033; chi-square test). Radiotherapy- and chemotherapy-induced toxicity did not differ from that previously reported. With a median follow-up of 65.46 months, a total of 10 recurrences have been diagnosed, all of them in stage III patients. Overall survival rate at five years was 76% for the complete population included.
  
  
  CONCLUSIONS
  Multidisciplinary treatment of resectable rectal cancer in a third-level hospital is feasible. Although efficacy results are comparable to those previously reported in the literature, further improvements in clinical staging as well as in adjuvant chemotherapy indication are desirable.
authors.affiliation: Department of Medical Oncology, Hospital General Universitario de Elche, Elche, Alicante, Spain. j.gallegoplazas@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Gallego-Plazas
authors.forename: F
authors.initials: F
authors.lastname: Menárguez-Pina
authors.forename: A
authors.initials: A
authors.lastname: Maestre-Peiró
authors.forename: V
authors.initials: V
authors.lastname: González-Orozco
authors.forename: F
authors.initials: F
authors.lastname: Andreu
authors.forename: M J
authors.initials: MJ
authors.lastname: Escudero-Barea
authors.forename: M A
authors.initials: MA
authors.lastname: Morcillo
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D008137:Longitudinal Studies; D009367:Neoplasm Staging; D012004:Rectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate